血液透析联合血液灌流治疗急性肾功能衰竭的临床研究

Clinical Study of Hemodialysis Combined with Hemoperfusion in the Treatment of Acute Renal Failure

目的:探讨血液透析(HD)联合血液灌流(HP)在急性肾功能衰竭治疗中的临床应用价值。方法:选择2010年1月至2013年1月期间于我院诊治的急性肾功能衰竭患者68例,在征得所有患者及家属同意情况下,按其就诊顺序进行编号并随机分为对照组(34例)和观察组(34例),给予对照组患者HD治疗,给予观察组患者HD+HP联合治疗,观察两组患者各临床指标并进行统计学对比分析。结果:观察组治疗有效率94.12%明显高于对照组88.24%,组间差异在统计学上有意义(P<0.05);观察组住院时间(14.76±4.01)d明显短于对照组(28.19±4.37)d,其并发症发生率8.82%亦明显低于对照组17.65%,以上组间差异均具有统计学意义(P<0.05);观察组患者HR(79.07±4.38)次/min、AP(68.19±7.48)mmHg、Scr(340.57±49.17)μmol/L、Bun(11.28±5.19)mol/L、K+(3.86±0.98)mmol/L、HCO(24.58±4.18)mmol/L等指标均明显优于对照组相应指标(91.42±4.51)次/min、(82.09±8.16)mmHg、(480.46±71.08)μmol/L、(19.45±8.17)mol/L、(4.94±1.07)mmol/L、(20.17±3.04)mmol/L,以上组间差异在统计学上均有意义(P<0.05)。结论:HD+HP联合治疗治疗急性肾衰竭安全、有效,且疗效佳、并发症少、患者恢复快、住院时间短,值得推广。

Objective：To investigate the application of hemodialysis （HD） and hemoperfusion （HP） in the treatment of acute renal failure therapy.Methods：68 cases of acute renal failure patients in our hospital from January 2010 to January 2013,Under the consent of all the patients and their families agree, the order number and their treatment were randomly divided into control group （34 cases） and observation group （34 cases）, the treatment given to patients with HD control group, the observation group were given a joint HD＋HP treatment,patients were observed in clinical indicators and statistical comparative analysis.Results：The treatment group had significantly higher efficiency 94.12%88.24%difference between the groups was statistically significant （P〈0.05）;observation group hospitalization time （14.76±4.01）d was significantly shorter than the control group （28.19±4.37）d, 8.82%of its complication rate was also significantly lower than the control group 17.65%, the difference between these groups were statistically significant（P〈0.05）;HR patients in the observation group （79.07±4.38） times/min,AP（68.19±7.48）mmHg,Scr（340.57±49.17）μmol/L,Bun（11.28±5.19）mol/L,K＋（3.86±0.98） mmol/L,HCO（24.58±4.18）mmol/L and other indicators were significantly corresponding index than the control group （91.42±4.51） times/min, （82.09± 8.16） mmHg, （480.46±71.08）μmol/L,（19.45±8.17） mol/L,（4.94±1.07） mmol/L,（20.17±3.04）mmol/L,differences between these groups were statistically significant（P〈0.05）.Conclusion：HD＋HP combination therapy in treatment of acute renal failure is safe, effective and good efficacy,fewer complications,patients recover faster, shorter hospital stay,worthy of promotion.